Identification of transporters associated with etoposide sensitivity of stomach cancer cell lines and methotrexate sensitivity of breast cancer cell lines by quantitative targeted absolute proteomics

Molecular Pharmacology

Volumn 83, Issue 2, 2013, Pages 490-500

  Obuchi, Wataru ^a   Ohtsuki, Sumio ^a,b   Uchida, Yasuo ^a   Ohmine, Ken ^a   Yamori, Takao ^c   Terasaki, Tetsuya ^a  

^a Graduate School of Pharmaceutical Sciences   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; GEMCITABINE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; REDUCED FOLATE CARRIER; REDUCED FOLATE CARRIER 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL LEVEL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; EMBRYO; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STEADY STATE; STOMACH CANCER; TANDEM MASS SPECTROMETRY;

BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; ETOPOSIDE; FEMALE; HUMANS; MCF-7 CELLS; MEMBRANE PROTEINS; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROPIONATES; PROTEOMICS; QUINOLINES; REPLICATION PROTEIN C; STOMACH NEOPLASMS;

EID: 84872742054     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.081083     Document Type: Article

References (37)

1. Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, and Scotto KW (1999) Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 5:3352-3356.
2. Assaraf YG (2007) Molecular basis of antifolate resistance. Cancer Metastasis Rev 26: 153-181.
3. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, and Kruh GD (2003) Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63:4048-4054.
4. Cole PD, Kamen BA, Gorlick R, Banerjee D, Smith AK, Magill E, and Bertino JR (2001) Effects of overexpression of gamma-glutamyl hydrolase on methotrexate metabolism and resistance. Cancer Res 61:4599-4604.
5. Ganapathy V, Thangaraju M, and Prasad PD (2009) Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 121:29-40.
6. Garrido W, Muñoz M, San Martín R, and Quezada C (2011) FK506 confers chemosensitivity to anticancer drugs in glioblastoma multiforme cells by decreasing the expression of the multiple resistance-associated protein-1. Biochem Biophys Res Commun 411:62-68.
7. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, and Bertino JR (1996) Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 335:1041-1048.
8. Kameyama R, Yamamoto Y, Izuishi K, Sano T, and Nishiyama Y (2011) Correlation of 18F-FLT uptake with equilibrative nucleoside transporter-1 and thymidine kinase-1 expressions in gastrointestinal cancer. Nucl Med Commun 32:460-465.
9. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y, Uchida Y, Ito S, and Terasaki T (2008) Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res 25:1469-1483.
10. Kawakami H, Ohtsuki S, Kamiie J, Suzuki T, Abe T, and Terasaki T (2011) Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. J Pharm Sci 100:341-352.
11. Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, Honma K, and Suzuki T (2001) Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 92:634-641.
12. Kühne A, Tzvetkov MV, Hagos Y, Lage H, Burckhardt G, and Brockmöller J (2009) Influx and efflux transport as determinants of melphalan cytotoxicity: resistance to melphalan in MDR1 overexpressing tumor cell lines. Biochem Pharmacol 78: 45-53.
13. Lage H (2003) Molecular analysis of therapy resistance in gastric cancer. Dig Dis 21: 326-338.
14. Leier I, Jedlitschky G, Buchholz U, Center M, Cole SP, Deeley RG, and Keppler D (1996) ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem J 314:433-437.
15. Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, and Keppler D (1994) The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 269:27807-27810.
16. Lewis WS, Cody V, Galitsky N, Luft JR, Pangborn W, Chunduru SK, Spencer HT, Appleman JR, and Blakley RL (1995) Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22. Kinetics, crystallography, and potential as selectable markers. J Biol Chem 270:5057-5064.
17. Li YC, Fung KP, Kwok TT, Lee CY, Suen YK, and Kong SK (2004) Mitochondria-targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells. Chemotherapy 50:55-62.
18. Löscher W and Potschka H (2005) Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2:86-98.
19. Lu X, Gong S, Monks A, Zaharevitz D, and Moscow JA (2002) Correlation of nucleoside and nucleobase transporter gene expression with antimetabolite drug cyto-toxicity. J Exp Ther Oncol 2:200-212.
20. Morant R (2001) Neoadjuvant and adjuvant chemotherapy of locally advanced stomach cancer. Onkologie 24:116-121.
21. Nakatsu N, Yoshida Y, Yamazaki K, Nakamura T, Dan S, Fukui Y, and Yamori T (2005) Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Mol Cancer Ther 4:399-412.
22. Nunoya K, Grant CE, Zhang D, Cole SP, and Deeley RG (2003) Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (mrp1). Drug Metab Dispos 31:1016-1026.
23. O'Brien C, Cavet G, Pandita A, Hu X, Haydu L, Mohan S, Toy K, Rivers CS, Mod-rusan Z, and Amler LC et al. (2008) Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res 68: 5380-5389.
24. Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, Ishiguro N, Kishimoto W, Ludwig-Schwellinger E, and Ebner T et al. (2012) Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos 40: 83-92.
25. Pinheiro C, Longatto-Filho A, Simões K, Jacob CE, Bresciani CJ, Zilberstein B, Cecconello I, Alves VA, Schmitt F, and Baltazar F (2009) The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Eur J Cancer 45:2418-2424.
26. Pinheiro C, Reis RM, Ricardo S, Longatto-Filho A, Schmitt F, and Baltazar F (2010) Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol 2010:427694.
27. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, and Borst P (2003) Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 63: 1094-1103.
28. Sharif KA, Moscow JA, and Goldman ID (1998) Concentrating capacity of the human reduced folate carrier (hRFC1) in human ZR-75 breast cancer cell lines. Biochem Pharmacol 55:1683-1689.
29. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, and Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234.
30. Takagaki K, Katsuma S, Kaminishi Y, Horio T, Nakagawa S, Tanaka T, Ohgi T, and Yano J (2004) Gene-expression profiling reveals down-regulation of equilibrative nucleoside transporter 1 (ENT1) in Ara-C-resistant CCRF-CEM-derived cells. J Biochem 136:733-740.
31. Uchida Y, Kamiie J, Ohtsuki S, and Terasaki T (2007) Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res 24:2281-2296.
32. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, and Terasaki T (2011) Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 117:333-345.
33. Volk EL and Schneider E (2003) Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63:5538-5543.
34. Waltham MC, Li WW, Gritsman H, Tong WP, and Bertino JR (1997) gamma-Glutamyl hydrolase from human sarcoma HT-1080 cells: characterization and inhibition by glutamine antagonists. Mol Pharmacol 51:825-832.
35. Wielinga P, Hooijberg JH, Gunnarsdottir S, Kathmann I, Reid G, Zelcer N, van der Born K, de Haas M, van der Heijden I, and Kaspers G et al. (2005) The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res 65:4425-4430.
36. Yamori T (2003) Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemother Pharmacol 52 (Suppl 1): S74-S79.
37. Zeng H, Chen ZS, Belinsky MG, Rea PA, and Kruh GD (2001) Transport of metho-trexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res 61:7225-7232.